Omnicell, Inc. (NASDAQ:OMCL) Receives $45.33 Consensus Target Price from Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been given a consensus recommendation of “Moderate Buy” by the seven research firms that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $46.7143.

A number of equities analysts recently weighed in on the stock. Bank of America upped their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Friday, May 23rd. Wells Fargo & Company upped their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, July 21st. Wall Street Zen lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Piper Sandler set a $55.00 price target on shares of Omnicell and gave the company an “overweight” rating in a research note on Monday, August 11th. Finally, Benchmark decreased their price target on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th.

Institutional Trading of Omnicell

A number of institutional investors have recently bought and sold shares of the stock. Johnson Financial Group Inc. acquired a new stake in Omnicell during the 4th quarter valued at approximately $37,000. Raymond James Financial Inc. purchased a new stake in Omnicell in the 2nd quarter worth $26,000. GAMMA Investing LLC boosted its stake in Omnicell by 37.1% during the 2nd quarter. GAMMA Investing LLC now owns 1,694 shares of the company’s stock worth $50,000 after purchasing an additional 458 shares during the last quarter. Point72 Hong Kong Ltd acquired a new position in shares of Omnicell during the 4th quarter valued at about $101,000. Finally, Corton Capital Inc. acquired a new position in shares of Omnicell during the 4th quarter valued at about $208,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Stock Up 0.7%

Shares of OMCL stock opened at $31.69 on Monday. Omnicell has a 12 month low of $22.66 and a 12 month high of $55.74. The stock has a market cap of $1.46 billion, a P/E ratio of 63.38, a P/E/G ratio of 9.18 and a beta of 0.78. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13. The company has a 50 day simple moving average of $29.45 and a two-hundred day simple moving average of $32.34.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.30 by $0.15. The business had revenue of $290.56 million during the quarter, compared to analysts’ expectations of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The firm’s revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.51 earnings per share. On average, research analysts expect that Omnicell will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.